Drug Search Results
More Filters [+]

Utreloxastat

Alternative Names: Utreloxastat, ptc-857, ptc 857, ptc857, epi-857, epi857
Latest Update: 2024-10-22
Latest Update Note: Clinical Trial Update

Product Description

PTC857, discovered through PTC's Bio-e platform, is an investigational small molecule drug that inhibits 15-Lipoxygenase, an enzyme that is a key regulator of the oxidative stress, protein aggregation and inflammation response pathways that underpin neurodegenerative disease pathology. The first indication planned for PTC857 is Parkinson's disease caused by a mutation in the GBA gene ("GBA Parkinson's disease"), which is one of the most common genetic subtypes of Parkinson's disease. (Sourced from: https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-first-patient-dosed-phase-1-trial)

Mechanisms of Action: ALOX15 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: PTC Therapeutics
Company Location: SOUTH PLAINFIELD NJ 07080-2449
Company CEO: Stuart W. Peltz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Utreloxastat

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Spain, Sweden, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Amyotrophic Lateral Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PTC857-CNS-001-ALS

P2

Unknown Status

Amyotrophic Lateral Sclerosis

2027-06-07

jRCT2011230040

P2

Recruiting

Amyotrophic Lateral Sclerosis

2025-07-31

jRCT2011230043

P2

Recruiting

Amyotrophic Lateral Sclerosis

2025-07-31

CARDINALS

P2

Active, not recruiting

Amyotrophic Lateral Sclerosis

2025-04-26

Recent News Events